Table 1. Characteristics of dabigatran users during the study period (N = 1215).

Variables	N	%
Age Groupsa
18–44	23	1.89
45–54	103	8.48
55–64	357	29.38
65+	732	60.25
Sex
Male	786	64.69
Region
East	110	9.05
North West	339	27.90
South	606	49.88
West	160	13.17
HAS-BLED Score Level over first three monthsb
0	308	25.35
1	541	44.53
>=2	366	30.12
Co-medication over first three monthsb
Proton pump inhibitors	303	24.94
Steroid	104	8.56
P-glycoprotein Inhibitor	73	6.01
Nonsteroidal anti-inflammatory drugs	180	14.81
Ever developed listed chronic conditionsc
renal failure	173	14.24
trauma	493	40.58
H. pylori infection	22	1.81

^aSummarized based on the information on Jul 01, 2010.

^bSummarized over the first three months of the observation period, i.e. from Jul 01, 2010 to Sep 30, 2010.

^cSummarized based on the whole observation period.